Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 29 articles:
HTML format
Text format



Single Articles


    November 2018
  1. KLUGER HM, Chiang V, Mahajan A, Zito CR, et al
    Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
    J Clin Oncol. 2018 Nov 8:JCO1800204. doi: 10.1200/JCO.18.00204.
    PubMed     Text format     Abstract available


    October 2018
  2. DAVAR D, Wang H, Chauvin JM, Pagliano O, et al
    Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.
    J Clin Oncol. 2018 Oct 25:JCO1800632. doi: 10.1200/JCO.18.00632.
    PubMed     Text format     Abstract available


  3. HAUSCHILD A, Dummer R, Schadendorf D, Santinami M, et al
    Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
    J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219.
    PubMed     Text format     Abstract available


    March 2018
  4. CARVAJAL RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, et al
    Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
    J Clin Oncol. 2018 Mar 12:JCO2017741090. doi: 10.1200/JCO.2017.74.1090.
    PubMed     Text format     Abstract available


    February 2018
  5. KHUSHALANI NI
    Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?
    J Clin Oncol. 2018 Feb 1:JCO2017768275. doi: 10.1200/JCO.2017.76.8275.
    PubMed     Text format     Abstract available


    January 2018
  6. HORIGUCHI M, Uno H, Wei LJ
    Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.
    J Clin Oncol. 2018 Jan 16:JCO2017760983. doi: 10.1200/JCO.2017.76.0983.
    PubMed     Text format    


    December 2017
  7. ROBERT C, Ribas A, Hamid O, Daud A, et al
    Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
    J Clin Oncol. 2017 Dec 28:JCO2017756270. doi: 10.1200/JCO.2017.75.6270.
    PubMed     Text format     Abstract available


  8. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
    Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
    J Clin Oncol. 2017;35:4066-4077.
    PubMed     Text format     Abstract available


  9. WONG SL, Faries MB, Kennedy EB, Agarwala SS, et al
    Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2017 Dec 12:JCO2017757724. doi: 10.1200/JCO.2017.75.7724.
    PubMed     Text format     Abstract available


    October 2017
  10. CARLINO MS, Sandhu S
    Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma.
    J Clin Oncol. 2017 Oct 19:JCO2017752055. doi: 10.1200/JCO.2017.75.2055.
    PubMed     Text format    


  11. CALLAHAN MK, Kluger H, Postow MA, Segal NH, et al
    Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
    J Clin Oncol. 2017 Oct 17:JCO2017722850. doi: 10.1200/JCO.2017.72.2850.
    PubMed     Text format     Abstract available


  12. LONG GV, Eroglu Z, Infante J, Patel S, et al
    Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
    J Clin Oncol. 2017 Oct 9:JCO2017741025. doi: 10.1200/JCO.2017.74.1025.
    PubMed     Text format     Abstract available


  13. CHESNEY J, Puzanov I, Collichio F, Singh P, et al
    Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
    J Clin Oncol. 2017 Oct 5:JCO2017737379. doi: 10.1200/JCO.2017.73.7379.
    PubMed     Text format     Abstract available


    September 2017
  14. SZNOL M, Ferrucci PF, Hogg D, Atkins MB, et al
    Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
    J Clin Oncol. 2017 Sep 15:JCO2016721167. doi: 10.1200/JCO.2016.72.1167.
    PubMed     Text format     Abstract available


    August 2017
  15. SCHADENDORF D, Wolchok JD, Hodi FS, Chiarion-Sileni V, et al
    Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
    J Clin Oncol. 2017 Aug 25:JCO2017732289. doi: 10.1200/JCO.2017.73.2289.
    PubMed     Text format     Abstract available


    July 2017
  16. LARKIN J, Minor D, D'Angelo S, Neyns B, et al
    Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    J Clin Oncol. 2017 Jul 3:JCO2016718023. doi: 10.1200/JCO.2016.71.8023.
    PubMed     Text format     Abstract available


    June 2017
  17. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Text format     Abstract available


    April 2017
  18. HAYDU LE, Scolyer RA, Lo S, Quinn MJ, et al
    Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.
    J Clin Oncol. 2017 Apr 4:JCO2016719393. doi: 10.1200/JCO.2016.71.9393.
    PubMed     Text format     Abstract available


    February 2017
  19. KOHN CG, Zeichner SB, Chen Q, Montero AJ, et al
    Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    J Clin Oncol. 2017 Feb 21:JCO2016696336. doi: 10.1200/JCO.2016.69.6336.
    PubMed     Text format     Abstract available


    January 2017
  20. AGARWALA SS, Lee SJ, Yip W, Rao UN, et al
    Phase III Randomized Study of 4 Weeks of High-Dose Interferon-alpha-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Rese
    J Clin Oncol. 2017 Jan 30:JCO2016702951. doi: 10.1200/JCO.2016.70.2951.
    PubMed     Text format     Abstract available


  21. D'ANGELO SP, Larkin J, Sosman JA, Lebbe C, et al
    Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
    J Clin Oncol. 2017;35:226-235.
    PubMed     Text format     Abstract available


  22. WATTS CG, Cust AE, Menzies SW, Mann GJ, et al
    Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
    J Clin Oncol. 2017;35:63-71.
    PubMed     Text format     Abstract available


    December 2016
  23. POWELL CA
    Pulmonary Infiltrates in a Patient With Advanced Melanoma.
    J Clin Oncol. 2016 Dec 28:JCO2016699793.
    PubMed     Text format     Abstract available


  24. DIENG M, Butow PN, Costa DS, Morton RL, et al
    Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2016;34:4405-4414.
    PubMed     Text format     Abstract available


  25. DAUD AI, Wolchok JD, Robert C, Hwu WJ, et al
    Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
    J Clin Oncol. 2016;34:4102-4109.
    PubMed     Text format     Abstract available


    November 2016
  26. NIJSTEN T
    Sunscreen Use in the Prevention of Melanoma: Common Sense Rules.
    J Clin Oncol. 2016;34:3956-3958.
    PubMed     Text format    


  27. WEBER JS, Hodi FS, Wolchok JD, Topalian SL, et al
    Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
    J Clin Oncol. 2016 Nov 14:JCO2015661389.
    PubMed     Text format     Abstract available


    September 2016
  28. GHIASVAND R, Weiderpass E, Green AC, Lund E, et al
    Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study.
    J Clin Oncol. 2016 Sep 12. pii: JCO675934.
    PubMed     Text format     Abstract available


    January 2016
  29. BULLOCH KJ, Narayan D, Ariyan S, Gould Rothberg BE, et al
    Correlation of body mass index with female survival benefit among a single-institution cohort of cutaneous melanomas >1 mm thick following wide-local excision and sentinel lymph node biopsy.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: